US equities
|
NVDA
$238.28
▲+1.85%
SPCX
$167.87
▲+5.60%
MU
$1,063.28
▼-1.08%
TSLA
$379.18
▲+2.32%
MSFT
$525.05
▲+1.45%
SNDK
$1,710.29
▼-0.56%
INTC
$117.01
▼-1.94%
META
$742.63
▲+2.00%
NVDA
$238.28
▲+1.85%
SPCX
$167.87
▲+5.60%
MU
$1,063.28
▼-1.08%
TSLA
$379.18
▲+2.32%
MSFT
$525.05
▲+1.45%
SNDK
$1,710.29
▼-0.56%
INTC
$117.01
▼-1.94%
META
$742.63
▲+2.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
RenovoRx, Inc. - Common Stock
(NQ:
RNXT
)
1.500
-0.080 (-5.07%)
Delayed Quote
Updated: 2:16 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about RenovoRx, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
RenovoRx Initiates Patient Enrollment at University of Texas Southwestern Medical Center for Pivotal Phase III TIGeR-PaC Clinical Trial
June 01, 2023
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Announces Late-Breaking Oral Presentation at 2023 ESMO World Congress on Gastrointestinal Cancer
May 25, 2023
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx to Present at the LD Micro Invitational XIII Conference
May 24, 2023
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Reports First Quarter 2023 Financial Results and Operational Highlights
May 15, 2023
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Sponsors Pancreatic Cancer Action Network’s PurpleStride® Event
May 01, 2023
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx to Participate in the Aegis Capital Virtual Conference on May 3, 2023
April 28, 2023
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Appoints Former Chief Medical Officer of Schering-Plough, Robert J. Spiegel, MD, FACP, to Board of Directors
April 27, 2023
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Presenting Phase III Clinical Trial Interim Analysis Data of the TIGeR-PaC Study at American Association for Cancer Research Annual Meeting Underway in Orlando, Florida
April 14, 2023
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Appoints Leesa Gentry as Senior Vice President of Clinical Operations
April 11, 2023
From
RenovoRx, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
April 03, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
↗
April 03, 2023
We're starting off the week with a breakdown of the biggest pre-market stock movers worth keeping an eye on Monday morning!
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
March 30, 2023
Via
Benzinga
RenovoRx, Inc. Announces $5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
March 30, 2023
From
RenovoRx, Inc.
Via
Business Wire
Why Bed Bath & Beyond Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
↗
March 30, 2023
Gainers SCYNEXIS, Inc. (NASDAQ: SCYX) shares climbed 68% to $2.8184 after the company announced an exclusive license agreement with GSK for Brexafemme, in which the company will receive an upfront...
Via
Benzinga
US Stocks Open Higher; Dow Jumps 150 Points
↗
March 30, 2023
U.S. stocks traded higher this morning, with the Dow Jones gaining around 150 points on Thursday. Following the market opening Thursday, the Dow traded up 0.48% to 32,874.88 while the NASDAQ rose 0.68%...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
March 30, 2023
Via
Benzinga
RenovoRx Announces Positive New Data from Phase III Clinical Trial Interim Analysis: 60% Survival Benefit and Fewer Side Effects than Systemic Chemotherapy
March 30, 2023
From
RenovoRx, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
March 29, 2023
Via
Benzinga
RenovoRx’s Principal Investigator of Phase III Clinical Trial Discusses Positive Interim Results on Patients with Locally Advanced Pancreatic Cancer on OncologyTube
↗
March 21, 2023
In the interview, Dr. Michael Pishvaian discussed the trial's potential impact on the oncology community as well as how pancreatic cancer patients are treated.
Via
Talk Markets
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
March 09, 2023
Via
Benzinga
RenovoRx's Targeted Prostate Cancer Treatment Shows Positive Trend In Median Overall Survival Versus Standard Care
↗
March 08, 2023
Via
Benzinga
RenovoRx Phase III Open Label TIGeR-PaC Interim Analysis Shows Promising Data That Support Continued Clinical Investigation of RenovoGemTM as a Treatment Option for Locally Advanced Pancreatic Cancer
March 08, 2023
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx, Inc. Full-year 2022 Results Provide Clues Supporting A Near-Term Catalyst-Fueled Breakout ($RNXT)
March 06, 2023
Via
AB Newswire
RenovoRx Reports Full Year 2022 Financial Results and Achievement of Important Phase III Clinical Study Milestone
March 02, 2023
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx, Inc. Shares Surge 117% YTD As Multiple Catalysts Come Into Focus ($RNXT)
March 02, 2023
Via
AB Newswire
RenovoRx to Present at the 35th Annual Roth Conference on March 13, 2023
March 01, 2023
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx, Inc. Shares Rally As RenovoTAMP Cancer Treatment Platform Continues To Attract Sector Attention ($RNXT)
March 01, 2023
Via
AB Newswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
February 28, 2023
Via
Benzinga
RenovoRX's Latest Innovative Technology Creates New Hope for Chemotherapy Patients
↗
February 14, 2023
RenovoRx takes existing chemotherapies and makes them more effective and less invasive at the same time, by being able to concentrate most of the chemotherapy agent on the tumor itself.
Via
Talk Markets
RenovoRx to Present at the Sequire Biotechnology Virtual Conference on February 2, 2023
January 25, 2023
From
RenovoRx, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
